<DOC>
	<DOCNO>NCT00699751</DOCNO>
	<brief_summary>ALSYMPCA ( ALpharadin SYMPtomatic Prostate CAncer ) international Phase III clinical study evaluate efficacy safety Radium-223 dichloride patient hormone refractory prostate cancer skeletal metastasis .</brief_summary>
	<brief_title>A Phase III Study Radium-223 Dichloride Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases</brief_title>
	<detailed_description>The aim study compare , patient symptomatic hormone refractory prostate cancer ( HRPC ) skeletal metastasis , efficacy best standard care plus Radium-223 dichloride versus best standard care plus placebo , primary efficacy endpoint overall survival ( OS ) . Patients randomise 2:1 allocation ratio ( Radium-223 dichloride : Placebo ) . The study treatment consist 6 intravenous administration Radium-223 dichloride placebo ( saline ) separate interval 4 week . The patient follow 3 year first study drug administration . Within U.S. , trial conduct IND sponsor Bayer HealthCare Pharmaceuticals . All patient receive BSoC ( Best Standard Care ) . This study original PCD 14 October 2010 , total 316 death observe ; result Independent Data Monitoring Committee 's ( IDMC 's ) recommendation stop study primary efficacy analysis overall survival cross pre-specified boundary efficacy . Later updated analysis primary endpoint first addendum do cut-off 15 July 2011 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Known hormone refractory disease Multiple skeletal metastasis ( â‰¥ 2 hot spot ) bone scintigraphy No intention use cytotoxic chemotherapy within next 6 month Either regular ( occasional ) analgesic medication use cancer relate bone pain treatment EBRT ( External Beam Radiation Therapy ) bone pain Treatment investigational drug within previous 4 week , plan treatment period Eligible first course docetaxel , i.e . patient fit enough , willing docetaxel available Treatment cytotoxic chemotherapy within previous 4 week , plan treatment period , failure recover adverse event due cytotoxic chemotherapy administer 4 week ago Systemic radiotherapy strontium89 , samarium153 , rhenium186 rhenium188 treatment bony metastasis within previous 24 week Other malignancy treat within last 5 year ( except nonmelanoma skin cancer lowgrade superficial bladder cancer ) History visceral metastasis , visceral metastasis assess abdominal/pelvic CT chest xray within previous 8 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>Bone Metastases</keyword>
	<keyword>Radium-223</keyword>
</DOC>